BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 26451959)

  • 1. Prognostic Role of Serum Antibody Immunity to p53 Oncogenic Protein in Ovarian Cancer: A Systematic Review and a Meta-Analysis.
    Garziera M; Montico M; Bidoli E; Scalone S; Sorio R; Giorda G; Lucia E; Toffoli G
    PLoS One; 2015; 10(10):e0140351. PubMed ID: 26451959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel algorithm to improve specificity in ovarian cancer detection.
    Arjomandi A; Delanoy ML; Walker RP; Binder SR
    Cancer Treat Res Commun; 2018; 15():32-35. PubMed ID: 30207285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating antibodies against p53 protein in patients with ovarian carcinoma. Correlation with clinicopathologic features and survival.
    Angelopoulou K; Rosen B; Stratis M; Yu H; Solomou M; Diamandis EP
    Cancer; 1996 Nov; 78(10):2146-52. PubMed ID: 8918407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic review: Tumor-associated antigen autoantibodies and ovarian cancer early detection.
    Fortner RT; Damms-Machado A; Kaaks R
    Gynecol Oncol; 2017 Nov; 147(2):465-480. PubMed ID: 28800944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer.
    Anderson KS; Wong J; Vitonis A; Crum CP; Sluss PM; Labaer J; Cramer D
    Cancer Epidemiol Biomarkers Prev; 2010 Mar; 19(3):859-68. PubMed ID: 20200435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P53 autoantibodies in sera from Danish ovarian cancer patients and their correlation with clinical data and prognosis.
    Høgdall EV; Høgdall CK; Blaakaer J; Heegaard NH; Glud E; Christensen L; Bock JE; Nørgaard-Pedersen B; Wiik A; Kjaer SK
    APMIS; 2002 Aug; 110(7-8):545-53. PubMed ID: 12390412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of serum and ascitic p53 autoantibodies in epithelial ovarian carcinoma.
    Abendstein B; Marth C; Müller-Holzner E; Widschwendter M; Daxenbichler G; Zeimet AG
    Cancer; 2000 Mar; 88(6):1432-7. PubMed ID: 10717627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer.
    Goodell V; Salazar LG; Urban N; Drescher CW; Gray H; Swensen RE; McIntosh MW; Disis ML
    J Clin Oncol; 2006 Feb; 24(5):762-8. PubMed ID: 16391298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the prognostic relevance of serum anti-p53 antibodies in epithelial ovarian cancer.
    Gadducci A; Ferdeghini M; Buttitta F; Cosio S; Fanucchi A; Annicchiarico C; Gagetti O; Bevilacqua G; Genazzani AR
    Gynecol Oncol; 1999 Jan; 72(1):76-81. PubMed ID: 9889034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-associated autoantibodies as early detection markers for ovarian cancer? A prospective evaluation.
    Kaaks R; Fortner RT; Hüsing A; Barrdahl M; Hopper M; Johnson T; Tjønneland A; Hansen L; Overvad K; Fournier A; Boutron-Ruault MC; Kvaskoff M; Dossus L; Johansson M; Boeing H; Trichopoulou A; Benetou V; La Vecchia C; Sieri S; Mattiello A; Palli D; Tumino R; Matullo G; Onland-Moret NC; Gram IT; Weiderpass E; Sánchez MJ; Navarro Sanchez C; Duell EJ; Ardanaz E; Larranaga N; Lundin E; Idahl A; Jirström K; Nodin B; Travis RC; Riboli E; Merritt M; Aune D; Terry K; Cramer DW; Anderson KS
    Int J Cancer; 2018 Aug; 143(3):515-526. PubMed ID: 29473162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoantibodies against HSF1 and CCDC155 as Biomarkers of Early-Stage, High-Grade Serous Ovarian Cancer.
    Wilson AL; Moffitt LR; Duffield N; Rainczuk A; Jobling TW; Plebanski M; Stephens AN
    Cancer Epidemiol Biomarkers Prev; 2018 Feb; 27(2):183-192. PubMed ID: 29141850
    [No Abstract]   [Full Text] [Related]  

  • 12. p53 autoantibodies, cytokine levels and ovarian carcinogenesis.
    Tsai-Turton M; Santillan A; Lu D; Bristow RE; Chan KC; Shih IeM; Roden RB
    Gynecol Oncol; 2009 Jul; 114(1):12-7. PubMed ID: 19398128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival of ovarian cancer patients overexpressing the tumour antigen p53 is diminished in case of MHC class I down-regulation.
    Leffers N; Lambeck AJ; de Graeff P; Bijlsma AY; Daemen T; van der Zee AG; Nijman HW
    Gynecol Oncol; 2008 Sep; 110(3):365-73. PubMed ID: 18571704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 Antibodies as a Diagnostic Marker for Cancer: A Meta-Analysis.
    Sobhani N; Roviello G; D'Angelo A; Roudi R; Neeli PK; Generali D
    Molecules; 2021 Oct; 26(20):. PubMed ID: 34684792
    [No Abstract]   [Full Text] [Related]  

  • 15. Prognostic Value of Circulating Tumor Cells in Ovarian Cancer: A Meta-Analysis.
    Zhou Y; Bian B; Yuan X; Xie G; Ma Y; Shen L
    PLoS One; 2015; 10(6):e0130873. PubMed ID: 26098665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Humoral p53 antibody response is a prognostic parameter in ovarian cancer.
    Mayerhofer K; Tempfer C; Kucera E; Hefler L; Zeisler H; Kainz C; Zeillinger R; Sliutz G
    Anticancer Res; 1999; 19(1B):875-8. PubMed ID: 10216509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic value of vascular endothelial growth factor in ovarian cancer: a systematic review and meta-analysis.
    Yu L; Deng L; Li J; Zhang Y; Hu L
    Gynecol Oncol; 2013 Feb; 128(2):391-6. PubMed ID: 23142075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of the p53 gene and presence of serum autoantibodies in ovarian cancer: correlation with differentiation.
    Green JA; Robertson LJ; Campbell IR; Jenkins J
    Cancer Detect Prev; 1995; 19(2):151-5. PubMed ID: 7750102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of anti-p53-autoantibodies in pancreatic disorders.
    Gansauge S; Gansauge F; Negri G; Galle P; Müller J; Nüssler AK; Poch B; Beger HG
    Int J Pancreatol; 1996 Jun; 19(3):171-8. PubMed ID: 8807362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
    Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
    Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.